Eli Lilly and Company (LLY) earnings on August 5, 2026
More Eli Lilly and Company earnings
Prior outlook: Pessimistic Outcome: Missed
Eli Lilly shares jumped after the company reported strong sales from its weight-loss treatments. The stock climbed as much as 8.9% during the day before settling at a 4.8% gain.
LLY price around the earnings
1169.86
Change: +4.7%
2026-08-05, 20:00 UTC
Start of the measured window
End of the measured window
1117.47
1149.58
1181.68
1213.79
1117.47
August 5, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Pessimistic Outcome: Missed
- Thesis published
- Results released
100% beat rate and analyst buy consensus offset by -11.23% RS, negative trend strength, legal uncertainty, and trajectory collapse.
Context analyzed before publication
- Trend
- Trajectory declined sharply from +17.5 to -32.8 over 5 days; trend strength deteriorated significantly pre-event.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.71
- Analysts covering the stock
- 26
- Average price target
- 1,276.96
- Lowest price target
- 850
- Highest price target
- 1,600
- Upside to price target
- 14.5%
- Quarterly earnings growth
- 168.1%
- Revenue growth
- 55.5%
- Forward EPS
- 45.08
- Trailing EPS
- 28
- Analyst moves in the last 60 days
- 10
- Strong buy: 5
- Buy: 17
- Hold: 4
- Sell: 1
- Strong sell: 1
- Strong buy
- 5
- Buy
- 17
- Hold
- 4
- Sell
- 1
- Strong sell
- 1
- July 15, 2026 · Citigroup: Maintains rating (Buy → Buy)
- July 14, 2026 · Bernstein: Maintains rating (Outperform → Outperform)
- July 13, 2026 · UBS: Maintains rating (Buy → Buy)
- July 13, 2026 · Guggenheim: Maintains rating (Buy → Buy)
- July 10, 2026 · B of A Securities: Maintains rating (Buy → Buy)
- July 8, 2026 · Truist Securities: Maintains rating (Buy → Buy)
- July 8, 2026 · Morgan Stanley: Maintains rating (Overweight → Overweight)
- July 8, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- July 7, 2026 · JP Morgan: Maintains rating (Overweight → Overweight)
- July 6, 2026 · Cantor Fitzgerald: Maintains rating (Overweight → Overweight)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
News
Sources (6)
- AMD, Walt Disney And 3 Stocks To Watch Heading Into Wednesday (opens in a new tab) — Benzinga
- $100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today (opens in a new tab) — Benzinga
- Eli Lilly Could Swing $65.9 Billion After Earnings (opens in a new tab) — Benzinga
- How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings (opens in a new tab) — Benzinga
- Amplia And Lilly Execute Clinical Trial Collaboration And Supply Agreement For Phase 1b/2b NSCLC Combination Study (opens in a new tab) — Benzinga
- Eli Lilly Could Swing Over $76 Billion In Value After Earnings (opens in a new tab) — Benzinga
Technicals
Evidence
- Price when the context was analyzed
- 1,117.47
- Average true range (ATR)
- 3.1%
- Distance to 52-week high
- -9.7%
- 14-day change (14d)
- -4.9%
- 30-day change (33d)
- -7.7%
- 30-day relative strength
- -11.2%
- SPY change (33d)
- +3.5%
- Nearest support
- 1,110.85
- Distance to nearest support
- 0.6%
- Nearest resistance
- 1,118.5
- Distance to nearest resistance
- 0.1%
- Volume accumulation ratio (14d / 46d)
- 0.9
- Mid: 1,110.85 (0.6% away, 0.19 ATR, 16 touches)
- Mid: 1,100.13 (1.6% away, 0.49 ATR, 5 touches)
- Mid: 1,093.45 (2.2% away, 0.68 ATR, 13 touches)
- Mid: 1,118.5 (0.1% away, 0.03 ATR, 11 touches)
- Mid: 1,126.63 (0.8% away, 0.26 ATR, 9 touches)
- Mid: 1,134.37 (1.5% away, 0.48 ATR, 16 touches)
Trends
Evidence
- Average earnings surprise
- +16.8%
- April 30, 2026: actual EPS 8.55 vs estimate 6.79 (surprise +25.9%)
- February 4, 2026: actual EPS 7.54 vs estimate 6.91 (surprise +9.1%)
- October 30, 2025: actual EPS 7.02 vs estimate 5.89 (surprise +19.1%)
- August 7, 2025: actual EPS 6.31 vs estimate 5.59 (surprise +12.9%)
Expected move
- Implied move
- +6.3%
- Source
- Options chain
Reactions over its last 20 earnings
- Median move
- 4.1%
- 75th percentile move
- 9.5%
- 90th percentile move
- 11.8%
- Up / down moves
- 12 / 8
- Average up move
- +6.3%
- Average down move
- -5.4%
Monitoring and close
What Eli Lilly and Company reported
- Status
- Finished
| Actual EPS | 8.38 |
|---|---|
| EPS estimate | 6.01 |
| EPS surprise | +39.4% |
| Revenue | $22,974 million |
| Revenue estimate | $20,725 million |
| Revenue surprise | +10.9% |
Eli Lilly beat expectations and raised annual forecast on strong Mounjaro and Zepbound sales. Market mixed today: Dow up, Nasdaq down; Uber, AMD and SpaceX fall.
Sources (43)
- Eli Lilly’s Weight-Loss Drug Demand Is Nearly Limitless. Here’s What Comes Next for the $1 Trillion Drugmaker (opens in a new tab) — 24/7 Wall St.
- CVS, Eli Lilly Forge Partnership on Improved GLP-1 Access; Companies Top Second-Quarter Views (opens in a new tab) — Yahoo
- Stock Market Midday, Aug. 5: Eli Lilly Pops and AMD Drops in Mixed Morning Markets (opens in a new tab) — Yahoo
- LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised (opens in a new tab) — Yahoo
- Eli Lilly's Weight-Loss Empire Keeps Expanding As Mounjaro, Zepbound Generate Nearly $15 Billion (opens in a new tab) — Benzinga
- SpaceX, Nvidia, Micron, AMD, Uber, CVS, Lilly, and More Stocks That Explain Today’s Market (opens in a new tab) — Barrons.com
- Nasdaq Falls Over 100 Points; Eli Lilly Shares Gain On Upbeat Earnings (opens in a new tab) — Benzinga
- CVS Targets Affordable GLP-1 Access With New Eli Lilly Deal (opens in a new tab) — Benzinga
- ADP Cools to +44K, Earnings Show Beats from DIS, LLY & More (opens in a new tab) — Zacks
- Eli Lilly CFO Says Expects Global Rollout Of Foundayo In All Major Markets In 2027 (opens in a new tab) — Benzinga
- Eli Lilly Stock: The One Question in Otherwise Perfect Earnings and What It Means for Shares (opens in a new tab) — Barrons.com
- Eli Lilly CFO Says Injectable GLP-1 Drugs Remain Key Growth Driver, Account For Three Out Of Four New Patient Starts (opens in a new tab) — Benzinga
- Lilly Stock Jumps on Strong GLP-1 Sales (opens in a new tab) — The Wall Street Journal
- Lilly (LLY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (opens in a new tab) — Zacks
- Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk (opens in a new tab) — Reuters
- Eli Lilly shares climb after stronger revenue outlook driven by obesity drugs (opens in a new tab) — InvestorsHub
- Eli Lilly stock soars on strong demand for weight-loss drugs (opens in a new tab) — Yahoo
- S&P 500 hits record high on Disney, Eli Lilly earnings (opens in a new tab) — Quartz
- Eli Lilly Stock Rises as Volume Growth Outruns Falling Prices (opens in a new tab) — Yahoo
- GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future (opens in a new tab) — Yahoo
- Eli Lilly's Weight-Loss Engine Is Still Accelerating (opens in a new tab) — GuruFocus.com
- Eli Lilly shares rise on revenue beat, raised outlook (opens in a new tab) — Yahoo
- Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’ (opens in a new tab) — Stocktwits
- Novo Nordisk looks to future proof as investors worry over pipeline (opens in a new tab) — Reuters Videos
- Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop (opens in a new tab) — Investor's Business Daily
- Eli Lilly Q2 Earnings Review: Breath-Taking Results Mean Higher Ceiling On Stock Price Target (opens in a new tab) — SeekingAlpha
- SpaceX, Nvidia, AMD, Eli Lilly, Uber, CVS, Disney, and More Stocks That Explain Today’s Market (opens in a new tab) — Barrons.com
- Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates (opens in a new tab) — Yahoo
- ADP labor data; Earnings from Eli Lilly, Sandisk, & Disney: What to watch on Wednesday (opens in a new tab) — Yahoo Finance Video
- Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soars (opens in a new tab) — Financial Times
- CVS Health Stock Climbs on Earnings Outlook Hike and Lilly Weight-Loss Drug Partnership (opens in a new tab) — Barrons.com
- Dow Jones Futures Rise; SpaceX, AMD Dive As Arista, Eli Lilly Jump With S&P 500 At Highs (opens in a new tab) — Investor's Business Daily
- Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles (opens in a new tab) — Barrons.com
- Eli Lilly shares pop as weight-loss drug demand fuels guidance hike (opens in a new tab) — Investing.com
- Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast (opens in a new tab) — Quartz
- CVS Health Q2 2026 earnings beat, Eli Lilly weight loss drug deal (opens in a new tab) — Quartz
- Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong (opens in a new tab) — Reuters
- Onsera Health Strengthens Cardiometabolic Care Delivery with Eli Lilly's(R) Oral GLP-1 Foundayo(R) (opens in a new tab) — Yahoo
- Eli Lilly (NYSE:LLY) Beats Expectations in Strong Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations (opens in a new tab) — StockStory
- Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$36.50 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est (opens in a new tab) — Benzinga
- Eli Lilly beat expectations with adjusted earnings of $8.38 per share and sales of $22.974 billion, above forecasts. — Benzinga
- Eli Lilly Q2 Adj. EPS $8.38 Beats $6.01 Estimate, Sales $22.974B Beat $20.725B Estimate (opens in a new tab) — Benzinga
- Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress (opens in a new tab) — Yahoo
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +5.0% pre-market, a move in line with the stock's usual reaction (about 4%). The figures overturn the prior pessimistic scenario. In the 1,275 similar cases in our market history, the close held that direction 86% of the time.
How the stock reacted
- Outcome
- Missed
- Consolidated
- +4.8%
- Max favorable move (MFE)
- 0%
- Max adverse move (MAE)
- 8.9%